Eyenovia
  • Home
  • About
    • About Eyenovia
    • Vision
    • Leadership
  • Technology
  • Pipeline
    • Eyenovia Pipeline
    • MydCombi (Mydriasis)
    • MicroLine (Presbyopia)
    • MicroPine (Myopia)
  • Partners
  • Investors
  • Careers
  • News + Resources
    • News
    • Resource Library
  • Menu Menu

Potential Lost Productivity Resulting from the Global Burden of Myopia

Myopia Control 2020–Where are we and where are we heading

Juvenile Myopia Progression, Risk Factors and Interventions

Five Year Clinical Trial on Atropine for the Treatment of Myopia 2

Facing the Myopia Epidemic

Atropine for treatment of childhood myopia in India (I-Atom)

Recent Posts

  • Eyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops January 13, 2023
  • Eyenovia Announces FDA Acceptance of New Drug Application for MydCombiâ„¢ for In-Office Pupil Dilation December 13, 2022
  • Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund November 29, 2022

Pipeline and Technology

  • MydCombi (Mydriasis)
  • MicroLine (Presbyopia)
  • MicroPine (Myopia)
  • Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com

Copyright © 2022 Eyenovia, Inc. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
  • Contact
  • Safe Harbor
  • Privacy Policy
  • Terms of Use
Scroll to top